BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Brise Pharmaceuticals and AbbVie Advance Migraine Drug Collaboration Worth Up to $757 Million

Brise Pharmaceuticals Co., Ltd. provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under ...

November 04, 2026 | News

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

November 03, 2026 | Regulatory

Zhimeng Biopharma Completes Enrolment of 255 Patients in Pivotal ALS Phase II/III Trial in China

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154,...

November 03, 2026 | News

APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...

November 02, 2026 | Analysis

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

October 30, 2026 | News

Japan's FY2027 Off-Year Drug Price Revision: 8 Numbers That Decide Who Pays

Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...

October 29, 2026 | Analysis

Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

October 29, 2026 | News

Enveda and Anthropic Cut Drug Batch Review Time by 89% Using Claude AI

In an internal evaluation, Claude-powered workflows reduced batch-record review time by 89% and produced a first draft of regulatory content in hours rat...

October 29, 2026 | News

Octant Secures FDA Orphan Drug Designation for OCT-980 to Treat Retinitis Pigmentosa

Octant, Inc. (“Octant”), a clinical-stage drug discovery company developing correctors for protein misfolding diseases, announced that th...

October 29, 2026 | News

MEPSGEN Launches NanoCalibur Mini to Accelerate Nanoparticle Formulation for Drug Discovery

Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro...

October 28, 2026 | News

Innovent Seeks China Approval for Sintilimab and Nolgileucel Combination in Advanced Melanoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

October 28, 2026 | News

EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...

October 28, 2026 | News

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

October 27, 2026 | Analysis

Stay Connected